The Global Uterine Fibroid Treatment Device Market was valued at USD 7 billion in 2024 and is estimated to grow at a CAGR of 7.2% to reach USD 13.8 billion by 2034. The consistent rise in fibroid cases among women of childbearing age is significantly fueling the demand for advanced treatment options that are both reliable and safe. Greater awareness about minimally invasive and uterus-sparing procedures, along with a noticeable shift towards technologically sophisticated solutions, is driving broader adoption across healthcare systems. Energy-based technologies have gained popularity for their ability to manage fibroids efficiently while maintaining uterine integrity.
Continuous innovation in non-invasive and less aggressive treatment methods is enhancing patient outcomes, particularly for those seeking alternatives to traditional surgery. The availability of skilled practitioners and expanded access to treatment across developed and emerging healthcare infrastructures also play a critical role in supporting market growth. As the prevalence of conditions like menorrhagia and other gynecologic disorders increases, the market for uterine fibroid treatment devices continues to expand. Companies like Canyon Medical, Minerva Surgical, Medtronic, Terumo Corporation, Johnson & Johnson (Ethicon), and others are key players advancing the landscape of fibroid management with novel therapeutic devices.
The surgical procedures segment generated USD 2.9 billion in 2024. These treatments focus on eliminating fibroids or, in certain situations, removing the uterus itself, depending on the extent and complexity of the condition. Procedures such as myomectomy and hysterectomy are often preferred when fibroids are large, numerous, or highly symptomatic. Their popularity among both healthcare providers and patients stems from high success rates and long-lasting relief from symptoms. The continued dominance of this segment is supported by an expanding healthcare infrastructure, improved insurance options, and better access to experienced surgical professionals. Factors like rising cases of excessive menstrual bleeding and related gynecological issues also contribute to the strong demand for surgical intervention.
In 2024, the invasive procedures segment led the market and is anticipated to grow at a CAGR of 7.1% through 2034. These treatments are especially effective for complicated or severe fibroid conditions, offering comprehensive symptom relief. When medications or non-invasive therapies fail to deliver the expected results, these methods become the preferred option. Open surgical approaches address persistent issues such as pelvic discomfort, abnormal bleeding, and fertility-related complications by providing more definitive outcomes compared to non-invasive techniques. The ability to treat deeply embedded or multiple fibroids also makes this segment a critical part of the uterine fibroid treatment device market.
U.S. Uterine Fibroid Treatment Device Market was valued at USD 3 billion in 2024. A key factor contributing to this growth is the availability of medical experts specializing in women’s health and gynecologic procedures. Thousands of energy-based and embolization procedures are carried out annually to treat fibroids effectively. With continual technological advancements in treatment devices and broader awareness of less invasive alternatives, the U.S. continues to be a significant contributor to overall market expansion. Education around newer treatment techniques and improvements in healthcare delivery models are also helping to increase patient uptake and trust in device-based fibroid solutions.
Prominent industry players include Olympus, Insightec, Shenzhen Mindray Bio-Medical Electronics, Conmed, Merit Medical Systems, CooperSurgical, Boston Scientific, Karl Storz, Hologic, Canyon Medical, Medtronic, Minerva Surgical, Terumo Corporation, Nesa Medtech, and Johnson & Johnson (Ethicon). These companies are instrumental in shaping the market's direction through ongoing product development and innovation. To reinforce their position in the uterine fibroid treatment device market, leading companies are actively investing in research and development to introduce minimally invasive technologies with improved safety profiles. Many are focusing on expanding their product portfolios through mergers, strategic partnerships, and acquisitions to access innovative treatment platforms. Several firms are working to enhance patient outcomes by integrating real-time imaging and AI-based navigation systems into their devices. Additionally, key players are increasing their global footprint by entering untapped markets and aligning with regional healthcare providers.
This product will be delivered within 2-4 business days.
Continuous innovation in non-invasive and less aggressive treatment methods is enhancing patient outcomes, particularly for those seeking alternatives to traditional surgery. The availability of skilled practitioners and expanded access to treatment across developed and emerging healthcare infrastructures also play a critical role in supporting market growth. As the prevalence of conditions like menorrhagia and other gynecologic disorders increases, the market for uterine fibroid treatment devices continues to expand. Companies like Canyon Medical, Minerva Surgical, Medtronic, Terumo Corporation, Johnson & Johnson (Ethicon), and others are key players advancing the landscape of fibroid management with novel therapeutic devices.
The surgical procedures segment generated USD 2.9 billion in 2024. These treatments focus on eliminating fibroids or, in certain situations, removing the uterus itself, depending on the extent and complexity of the condition. Procedures such as myomectomy and hysterectomy are often preferred when fibroids are large, numerous, or highly symptomatic. Their popularity among both healthcare providers and patients stems from high success rates and long-lasting relief from symptoms. The continued dominance of this segment is supported by an expanding healthcare infrastructure, improved insurance options, and better access to experienced surgical professionals. Factors like rising cases of excessive menstrual bleeding and related gynecological issues also contribute to the strong demand for surgical intervention.
In 2024, the invasive procedures segment led the market and is anticipated to grow at a CAGR of 7.1% through 2034. These treatments are especially effective for complicated or severe fibroid conditions, offering comprehensive symptom relief. When medications or non-invasive therapies fail to deliver the expected results, these methods become the preferred option. Open surgical approaches address persistent issues such as pelvic discomfort, abnormal bleeding, and fertility-related complications by providing more definitive outcomes compared to non-invasive techniques. The ability to treat deeply embedded or multiple fibroids also makes this segment a critical part of the uterine fibroid treatment device market.
U.S. Uterine Fibroid Treatment Device Market was valued at USD 3 billion in 2024. A key factor contributing to this growth is the availability of medical experts specializing in women’s health and gynecologic procedures. Thousands of energy-based and embolization procedures are carried out annually to treat fibroids effectively. With continual technological advancements in treatment devices and broader awareness of less invasive alternatives, the U.S. continues to be a significant contributor to overall market expansion. Education around newer treatment techniques and improvements in healthcare delivery models are also helping to increase patient uptake and trust in device-based fibroid solutions.
Prominent industry players include Olympus, Insightec, Shenzhen Mindray Bio-Medical Electronics, Conmed, Merit Medical Systems, CooperSurgical, Boston Scientific, Karl Storz, Hologic, Canyon Medical, Medtronic, Minerva Surgical, Terumo Corporation, Nesa Medtech, and Johnson & Johnson (Ethicon). These companies are instrumental in shaping the market's direction through ongoing product development and innovation. To reinforce their position in the uterine fibroid treatment device market, leading companies are actively investing in research and development to introduce minimally invasive technologies with improved safety profiles. Many are focusing on expanding their product portfolios through mergers, strategic partnerships, and acquisitions to access innovative treatment platforms. Several firms are working to enhance patient outcomes by integrating real-time imaging and AI-based navigation systems into their devices. Additionally, key players are increasing their global footprint by entering untapped markets and aligning with regional healthcare providers.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, By Technology, 2021 - 2034 ($ Mn)
Chapter 6 Market Estimates and Forecast, By Treatment, 2021 - 2034 ($ Mn)
Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)
Chapter 8 Company Profiles
Companies Mentioned
- Boston Scientific
- Canyon Medical
- Conmed
- CooperSurgical
- Hologic
- Insightec
- Johnson & Johnson (Ethicon)
- Karl Storz
- Medtronic
- Merit Medical Systems
- Minerva Surgical
- Nesa Medtech
- Olympus
- Shenzhen Mindray Bio-Medical Electronics
- Terumo Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | June 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 7 Billion |
| Forecasted Market Value ( USD | $ 13.8 Billion |
| Compound Annual Growth Rate | 7.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
